A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Abstract

A phase III, randomized, placebo-controlled study of belimumab.Biological therapy of SLE with belimumab, effect and advers events of therapy, results of study.Patients with systemic lupus erythematosus.

Keywords

• SLE
• belimumab
• results of study